RoboSense Reached Strategic Partnership with WeRide to Promote Large-scale Commercial Application of Autonomous Driving Technologies
10.6.2022 15:00:00 EEST | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, today announced strategic partnership with WeRide, a global leading Level 4 autonomous driving technology company. This partnership will assist WeRide in accelerating its on-board application of automotive-grade smart solid-state LiDAR and speed up the large-scale series production and commercial application of autonomous driving technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220610005230/en/
RoboSense Reached Strategic Partnership with WeRide (Photo: Business Wire)
Chunchao Qiu, co-founder and executive president of RoboSense, commented on this strategic partnership: “We have been exploring the autonomous driving industry for years and we are about to see exponential growth in the large-scale commercial application of autonomous driving technologies thanks to the decisively positive macro environment. RoboSense has reached in-depth strategic partnership with WeRide, to support WeRide in achieving production and application of autonomous vehicles faster, more efficiently and on a larger scale with our large-scale production and delivery capacity of the leading smart solid-state LiDAR products, and to further deepen the auto industry reform by making pragmatic, bold and innovative efforts as a technology enterprise.”
Tony Han, founder and CEO of WeRide said: “With the strong support from RoboSense, WeRide gained rich experience in the application of solid-state LiDAR to autonomous vehicles and formed ideal solutions. The sensor kit has been further optimized in terms of size and power consumption, while maintaining consistent accuracy, stability and safety in handling increasingly complex urban traffic conditions in China. This gives our next-generation SAE L2-L4 autonomous driving solution a strong competitive edge."
Constant technological innovation, aim at commercial application, and focus on large-scale production are the basis of this partnership. Currently, RoboSense has connected with a number of upstream and downstream partners in the industry to integrate advantageous resources and establish a complete supply chain. Deployment of a number of smart production lines of RoboSense in Guangzhou, Shenzhen and other cities are basically completed, with an expected annual production capacity of one million units, which guarantees a continuous and stable supply of advanced and reliable products for WeRide and other partners.
Based on this strategic cooperation, the two parties will continue to deepen industrial integration through technological innovation to provide consumers with a safer, more comfortable, convenient and normalized autonomous driving travel experience.
About WeRide
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 15 cities around the world.
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. Its mission is to innovate outstanding hardware and AI capabilities to create smart solutions that enable robots, including autonomous vehicles, to have perception capabilities superior to humans.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005230/en/
Contact information
Grace Ye
media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom